Literature DB >> 31279990

Temporal trends in incidence of childhood cancer in Switzerland, 1985-2014.

Grit Sommer1, Matthias Schindler2, Shelagh Redmond3, Verena Pfeiffer4, Garyfallos Konstantinoudis5, Roland A Ammann6, Marc Ansari7, Heinz Hengartner8, Gisela Michel9, Claudia E Kuehni10.   

Abstract

BACKGROUND: Incidence of childhood cancer increased in most countries worldwide, but reasons are unclear. This study investigates trends of childhood cancer incidence in Switzerland from 1985 to 2014.
METHODS: We extracted data on all childhood cancer cases diagnosed at ages 0-14 years in Switzerland from the Swiss Childhood Cancer Registry. We included ICCC-3 main groups I-XII and calculated age-standardised, cumulative, and age-specific incidence for different diagnostic groups. We analysed trends of annual age-standardised incidence using JoinPoint regression models.
RESULTS: Over the study period from 1985 to 2014, 5104 of 5486 cancer diagnoses (93%) were microscopically verified. The proportion of children treated in paediatric cancer centres increased from 84% during 1985-1994 to 93% in 1995-2004 and 98% in 2005-2014 (p < 0.001). Using the World standard population, age-standardised incidence was 143 in 1985-1994, 154 in 1995-2004, and 162 per million in 2005-2014. Incidence increased by 0.7% (95% confidence interval (CI) 0.5; 1.0) per year for all cancers from 1985 to 2014, 0.8% (95% CI 0.2%-1.4%) for leukaemias over the same period, 3.0% (95% CI 0.2%-1.4%) for CNS tumours during 1985-2002, and 3.8% (95% CI 1.7%-6.0%) for epithelial neoplasms and melanomas over the period 1985-2014.
CONCLUSION: Trends in incidence were driven mostly by increases among leukaemias and CNS tumours. For CNS tumours, observed trends may be explained at least partially by diagnostic changes and improved registration. For leukaemias, rising incidence may be real and due to risk factors that experience similar increases in trends.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Infant; Neoplasms; Population-based study; Registry

Mesh:

Year:  2019        PMID: 31279990     DOI: 10.1016/j.canep.2019.06.002

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Childhood cancers in a section of the South African private health sector: Analysis of medicines claims data.

Authors:  Marianne N Otoo; Martie S Lubbe; Hanlie Steyn; Johanita R Burger
Journal:  Health SA       Date:  2020-09-30

2.  A comparison of the burden of lung cancer attributable to tobacco exposure in China and the USA.

Authors:  Xiaomei Wu; Bo Zhu; Shuang Xu; Yong Liu; Yifei Bi; Baosen Zhou
Journal:  Ann Transl Med       Date:  2020-11

3.  Persistently high incidence rates of childhood acute leukemias from 2010 to 2017 in Mexico City: A population study from the MIGICCL.

Authors:  Janet Flores-Lujano; David Aldebarán Duarte-Rodríguez; Elva Jiménez-Hernández; Jorge Alfonso Martín-Trejo; Aldo Allende-López; José Gabriel Peñaloza-González; María Luisa Pérez-Saldivar; Aurora Medina-Sanson; José Refugio Torres-Nava; Karina Anastacia Solís-Labastida; Luz Victoria Flores-Villegas; Rosa Martha Espinosa-Elizondo; Raquel Amador-Sánchez; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; Nora Nancy Núñez-Villegas; Ana Itamar González-Ávila; María de Los Ángeles Del Campo-Martínez; Martha Alvarado-Ibarra; Vilma Carolina Bekker-Méndez; Rocío Cárdenas-Cardos; Silvia Jiménez-Morales; Roberto Rivera-Luna; Haydee Rosas-Vargas; Norma C López-Santiago; Angélica Rangel-López; Alfredo Hidalgo-Miranda; Elizabeth Vega; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; José Arellano-Galindo; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré
Journal:  Front Public Health       Date:  2022-09-14

4.  Cancer survivors present significantly lower long-term stability of orthodontic treatment: a prospective case-control study.

Authors:  Maria Mitus-Kenig; Marcin Derwich; Ewa Czochrowska; Elzbieta Pawlowska
Journal:  Eur J Orthod       Date:  2021-12-01       Impact factor: 3.075

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.